Go Deep
Anavex Life Sciences Corp.
Anavex Life Sciences Corp. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 22,669 | -10.6 | 1.22 | 0.00 | 140.95 |
| Oct 2026 | 22,659 | -10.6 | 1.23 | 0.00 | 141.47 |
| Oct 2026 | 22,669 | -10.6 | 1.22 | 0.00 | 140.54 |
| Oct 2026 | 22,829 | -9.4 | 1.08 | 0.00 | 124.08 |
| Oct 2026 | 20,686 | -8.9 | 1.03 | 0.00 | 118.52 |
| Oct 2026 | 20,582 | -9.7 | 1.12 | 0.00 | 128.95 |
| Oct 2026 | 20,582 | -9.7 | 1.12 | 0.00 | 128.63 |
| Oct 2026 | 20,575 | -9.7 | 1.12 | 0.00 | 128.37 |
Anavex Life Sciences Corp. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | 7,824,000.0 | -5,338,000.0 | -5,681,000.0 | -9,827,000.0 |
| EPS | 0.1 | -0.1 | -0.1 | -0.1 |
Anavex Life Sciences Corp. Revenue & Profit: Last 4 Years
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -46,377,000.0 | -43,002,000.0 | -47,505,000.0 | -47,978,000.0 |
| EPS | -0.5 | -0.5 | -0.6 | -0.6 |
Anavex Life Sciences Corp. Balance Sheet
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Total Assets | 103,815,000.0 | 135,567,000.0 | 154,386,000.0 | 152,705,000.0 |
| Total Liabilities | 8,946,000.0 | 15,304,000.0 | 12,534,000.0 | 10,214,000.0 |
| Total Equity | 94,869,000.0 | 120,263,000.0 | 141,852,000.0 | 142,491,000.0 |
Owes vs Owns
Anavex Life Sciences Corp. owed $0.06 for every $1 it owned in Jun 2026, about the same as $0.07 in Sep 2022.
| Period | Jun 2026 | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.06× | 0.09× | 0.11× | 0.08× | 0.07× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Anavex Life Sciences Corp. Assets & Liabilities Breakdown (USD millions)
What it owns — Sep 2025
Cash & short-term investments 98.8%Receivables 0.8%
How it's funded — Sep 2025
Payables 4.1%Other liabilities 4.5%Shareholders' equity 91.4%
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 102.6 | 132.2 | 151.0 | 149.2 |
| Receivables | 0.8 | 2.4 | 2.7 | 3.2 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 0.0 | 0.0 | 0.0 | 0.0 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 0.4 | 0.9 | 0.7 | 0.4 |
| Liabilities & equity | ||||
| Short-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term debt | 0.0 | 0.0 | 0.0 | 0.0 |
| Payables | 4.2 | 9.6 | 4.3 | 3.8 |
| Other liabilities | 4.7 | 5.7 | 8.2 | 6.4 |
| Shareholders' equity | 94.9 | 120.3 | 141.9 | 142.5 |
| Net tangible assets | 94.9 | 120.3 | 141.9 | 142.5 |
Anavex Life Sciences Corp. Cash Flow
| Line Item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 |
|---|---|---|---|---|
| Operating Activities | -39,044,000.0 | -30,812,000.0 | -27,785,000.0 | -24,238,000.0 |
| Financing Activities | 9,434,000.0 | 11,975,000.0 | 29,651,000.0 | 21,288,000.0 |